SK282061B6 - Makrolidy, spôsob ich prípravy a farmaceutický prostriedok - Google Patents

Makrolidy, spôsob ich prípravy a farmaceutický prostriedok Download PDF

Info

Publication number
SK282061B6
SK282061B6 SK435-93A SK43593A SK282061B6 SK 282061 B6 SK282061 B6 SK 282061B6 SK 43593 A SK43593 A SK 43593A SK 282061 B6 SK282061 B6 SK 282061B6
Authority
SK
Slovakia
Prior art keywords
group
hydroxy
formula
compounds
iii
Prior art date
Application number
SK435-93A
Other languages
English (en)
Slovak (sk)
Other versions
SK43593A3 (en
Inventor
Karl Baumann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929209815A external-priority patent/GB9209815D0/en
Priority claimed from GB939304927A external-priority patent/GB9304927D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK43593A3 publication Critical patent/SK43593A3/sk
Publication of SK282061B6 publication Critical patent/SK282061B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
SK435-93A 1992-05-07 1993-05-05 Makrolidy, spôsob ich prípravy a farmaceutický prostriedok SK282061B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929209815A GB9209815D0 (en) 1992-05-07 1992-05-07 Organic compounds,processes for their production and their use
GB939304927A GB9304927D0 (en) 1993-03-10 1993-03-10 Organic compounds

Publications (2)

Publication Number Publication Date
SK43593A3 SK43593A3 (en) 1995-07-11
SK282061B6 true SK282061B6 (sk) 2001-10-08

Family

ID=26300836

Family Applications (1)

Application Number Title Priority Date Filing Date
SK435-93A SK282061B6 (sk) 1992-05-07 1993-05-05 Makrolidy, spôsob ich prípravy a farmaceutický prostriedok

Country Status (25)

Country Link
US (1) US5514685A (de)
EP (1) EP0569337B1 (de)
JP (1) JP2788392B2 (de)
KR (1) KR100292311B1 (de)
CN (1) CN1037773C (de)
AT (1) ATE155787T1 (de)
AU (1) AU668152B2 (de)
CA (1) CA2095659C (de)
CY (1) CY2126B1 (de)
CZ (1) CZ291773B6 (de)
DE (1) DE69312386T2 (de)
DK (1) DK0569337T3 (de)
ES (1) ES2105193T3 (de)
FI (2) FI102612B (de)
GR (1) GR3024754T3 (de)
HU (2) HUT66531A (de)
IL (1) IL105607A (de)
MY (1) MY109602A (de)
NO (1) NO305865B1 (de)
NZ (1) NZ247553A (de)
PH (1) PH30456A (de)
RU (1) RU2126009C1 (de)
SG (1) SG47011A1 (de)
SK (1) SK282061B6 (de)
TW (1) TW330936B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
JP4155593B2 (ja) 1994-10-26 2008-09-24 ノバルティス・アクチエンゲゼルシャフト 医薬組成物
MY129435A (en) 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
PT2198858E (pt) 1998-03-26 2011-09-01 Astellas Pharma Inc Composição farmacêutica de libertação constante que contém um macrólido como o tacrolimus
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
CA2492989C (en) 2002-07-23 2012-11-20 Novartis Ag Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
KR100469917B1 (ko) * 2002-09-09 2005-02-02 (주)조은식품 구수한 호박씨가 첨가된 호박엿 및 그 제조방법
KR100745493B1 (ko) * 2005-12-16 2007-08-03 주식회사농심 조직감이 향상된 사출 스낵 및 그 제조 방법
US8716293B2 (en) * 2010-04-02 2014-05-06 Janssen R&D Ireland Macrocyclic integrase inhibitors
ES2898849T3 (es) 2014-10-28 2022-03-09 Koushi Yamaguchi Medicamento para mejorar el síndrome de hipertensión inducida por el embarazo
JP7465806B2 (ja) 2018-08-10 2024-04-11 晃史 山口 母体と胎児との関係における液性免疫関連疾患の治療薬
WO2020129348A1 (ja) 2018-12-18 2020-06-25 晃史 山口 不妊・不育症または妊娠状態を改善するための薬剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5254562A (en) * 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CA1316916C (en) * 1988-10-12 1993-04-27 David Askin Hydroxide mediated fk-506 rearrangement product
EP0364031B1 (de) * 1988-10-12 1992-12-23 Merck & Co. Inc. Verfahren zur Umlagerung von FK-506 unter Beteiligung von Hydroxid
KR920700212A (ko) * 1989-06-14 1992-02-19 쟝 크라머·한스 루돌프 하우스 헤테로원자-함유 트리사이클릭 화합물
EP0413532A3 (en) * 1989-08-18 1991-05-15 Fisons Plc Macrocyclic compounds
IE904050A1 (en) * 1989-11-13 1991-05-22 Merck & Co Inc Aminomacrolides and derivatives having immunosuppressive¹activity
US5260301A (en) * 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
GB2246350A (en) * 1990-07-23 1992-01-29 Fujisawa Pharmaceutical Co Tricyclo compounds
EP0480623A1 (de) * 1990-10-11 1992-04-15 Merck & Co. Inc. Halomakrolide und Derivate mit immunosuppressiver Wirkung
WO1992013862A1 (en) * 1991-02-05 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Lactone compounds
JPH06510304A (ja) * 1991-09-05 1994-11-17 アボツト・ラボラトリーズ 大環状イムノモジュレーター

Also Published As

Publication number Publication date
MY109602A (en) 1997-03-31
FI102612B1 (fi) 1999-01-15
EP0569337B1 (de) 1997-07-23
CZ291773B6 (cs) 2003-05-14
HUT66531A (en) 1994-12-28
JPH0641144A (ja) 1994-02-15
KR940005631A (ko) 1994-03-22
DE69312386T2 (de) 1998-01-29
CA2095659C (en) 2005-08-09
CY2126B1 (en) 2002-06-21
KR100292311B1 (ko) 2001-09-17
CN1083486A (zh) 1994-03-09
CZ82993A3 (en) 1994-01-19
PH30456A (en) 1997-05-28
FI102612B (fi) 1999-01-15
FI932035A (fi) 1993-11-08
EP0569337A1 (de) 1993-11-10
AU3839393A (en) 1993-11-11
NO305865B1 (no) 1999-08-09
NZ247553A (en) 1995-07-26
IL105607A0 (en) 1993-09-22
DE69312386D1 (de) 1997-08-28
JP2788392B2 (ja) 1998-08-20
NO931627D0 (no) 1993-05-05
GR3024754T3 (en) 1997-12-31
SG47011A1 (en) 1998-03-20
CA2095659A1 (en) 1993-11-08
NO931627L (no) 1993-11-08
HU211135A9 (en) 1995-10-30
HU9301190D0 (en) 1993-07-28
FI982476A0 (fi) 1998-11-16
US5514685A (en) 1996-05-07
IL105607A (en) 1998-01-04
FI932035A0 (fi) 1993-05-05
RU2126009C1 (ru) 1999-02-10
AU668152B2 (en) 1996-04-26
ATE155787T1 (de) 1997-08-15
TW330936B (en) 1998-05-01
DK0569337T3 (da) 1998-01-19
SK43593A3 (en) 1995-07-11
CN1037773C (zh) 1998-03-18
ES2105193T3 (es) 1997-10-16

Similar Documents

Publication Publication Date Title
DE69021833T2 (de) Heteroatome enthaltende tricyclische Verbindungen.
DE69333577T2 (de) Rapamycin-Derivate und ihre Verwendung, insbesondere als Immunosuppressoren
SK282061B6 (sk) Makrolidy, spôsob ich prípravy a farmaceutický prostriedok
DE60309909T2 (de) Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen
AU683463B2 (en) New prednisolone derivates
HUT73418A (en) Process for preparing rapamycin carbonate esters and pharmaceutical compositions of immunosuppressive activity containing said compounds
RU2130460C1 (ru) Производные тетрагидропирана и фармацевтическая композиция на их основе
EP0402931A1 (de) Heteroatome enthaltende tricyclische Verbindungen
EP2512485A1 (de) Neuartige pgp-steroidhemmer zur verwendung als hemmer von multidrug-resistenz
JPH04230388A (ja) ヘテロ原子含有三環式化合物
US5266566A (en) Method of treating fungal infections using sterodial ester compounds
DE69901907T2 (de) Fotocyclisierte rapamycine
KR100317009B1 (ko) 테트라하이드로피란유도체
PL173506B1 (pl) Związki tricykliczne zawierające heteroatomy
DE19963266A1 (de) Steroidale Hemmstoffe der Lp(a)-Biosynthese
PL176409B1 (pl) Pochodne tetrahydropiranu, sposób ich wytwarzania i zawierająca je kompozycja farmaceutyczna

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20110505